ArticleInflammation2014
Inhibitions of NF-κB and TNF-α result in differential effects in rats with acute on chronic liver failure induced by d-Gal and LPS.
Article in Inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Acute-on-chronic liver failure: From definition to pathogenesis and therapy.Chinese medical journal · 2026Review
- Acute-on-chronic liver failure and immune dysregulation: Systemic inflammation and immunoparesis paradox.Hepatology communications · 2026Review
- Targeted animal models for preclinical assessment of cellular and gene therapies in pancreatic and liver diseases: regulatory and practical insights.Cytotherapy · 2025Review
- [Progress in clinical research on potential therapeutic drugs for acute-on-chronic liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Effect of silymarin on the relative gene expressions of some inflammatory cytokines in the liver of CClScientific reports · 2023Article
- Protective effects of glutamine on lipopolysaccharide/D-galactosamine-induced fulminant hepatitis in mice.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- The progress to establish optimal animal models for the study of acute-on-chronic liver failure.Frontiers in medicine · 2023Review
- Animal models applied to acute-on-chronic liver failure: Are new models required to understand the human condition?World journal of clinical cases · 2022Review
- Network pharmacology-based prediction of active compounds in the Wenyang Jiedu Huayu formula acting on acute-on-chronic liver failure with experimental supportFrontiers in pharmacology · 2022Article
- Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice.Iranian journal of medical sciences · 2021Article
- Lysimachiae Herba Inhibits Inflammatory Reactions and Improves Lipopolysaccharide/D-Galactosamine-Induced Hepatic Injury.Antioxidants (Basel, Switzerland) · 2021Article
- Forsythia Fruit Prevents Fulminant Hepatitis in Mice and Ameliorates Inflammation in Murine Macrophages.Nutrients · 2021Article
- Stattic alleviates acute hepatic damage induced by LPS/d-galactosamine in mice.Innate immunity · 2021Article
- Efficacy ofFood science & nutrition · 2020Article
- Succinate dehydrogenase inhibitor dimethyl malonate alleviates LPS/d-galactosamine-induced acute hepatic damage in mice.Innate immunity · 2019Article
- Establishment of a new acute-on-chronic liver failure model.Acta pharmaceutica Sinica. B · 2017Article
- Recombinant adenovirus containing hyper-interleukin-6 and hepatocyte growth factor ameliorates acute-on-chronic liver failure in rats.World journal of gastroenterology · 2016Article
- Improved prescription of taohechengqi-tang alleviates D-galactosamine acute liver failure in rats.World journal of gastroenterology · 2016Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels.Biomaterials · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we induced an acute-on-chronic liver failure (ACLF) model by human serum albumin (HSA), D-galactosamine (D-Gal) and lipopolysaccharide (LPS) in rats. Anti-TNF-α polyclonal antibody (as TNF-α inhibitor) and pyrrolidine dithiocarbamate (PDTC, a NF-κB inhibitor) were used to treat the liver failure animals, respectively. The results showed that TNF-α inhibition was beneficial, but NF-κB inhibition failed to protect the rats in ACLF. However, HMGB1 levels, cytokine production and activation of TLR4-NF-κB signaling pathway were all suppressed by both TNF-α and NF-κB inhibition. In order to verify the effect of PDTC on inflammatory response, we further explored its effect in vitro. Anti-inflammatory activity of PDTC was proved in U937 cell line. To conclude, both inhibitions of TNF-α and NF-κB are able to suppress the activation of TLR4 and NF-κB signaling pathway. However, NF-κB inhibition with PDTC failed to protect the rats in ACLF induced by D-Gal and LPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.